Delta Biosciences will provide space-as-a-service life-science experimentation capabilities aboard Starlab, supporting chemical stability research, biological studies and medical technology validation in low Earth orbit.
HOUSTON – March 17, 2026 – Starlab Space LLC, a commercial space station developer, today announced a reservation from Delta Biosciences, a life-sciences mission integrator that enables companies to conduct applied research in orbit and generate results for terrestrial product development. The partnership will make microgravity research more accessible as the commercial space industry transitions beyond the International Space Station.
Through the reservation, Delta Biosciences will provide life-science experimentation capability aboard Starlab across three primary areas: chemical stability and formulation research, biological and bioreactor studies, and payload and medical technology validation. Delta Biosciences operates under a space-as-a-service model, designing missions, developing experimental payloads and flight hardware, and delivering post-flight analytical data to support R&D, intellectual property strategy, and regulatory decision-making. This model enables partners to generate in-orbit evidence without building independent flight programs.
“Microgravity and space radiation reveal the limits of medicines, materials, and biological systems,” said Dominykas (Dom) Milasius, Co-Founder of Delta Biosciences. “And when used deliberately, allow us to improve and redesign them. Our mission is to turn the space environment into a practical R&D platform for life sciences. This partnership with Starlab will deliver sustained capability that supports both scientific exploration and commercial return from in-space experimentation.”
“Delta Biosciences brings a practical, mission-driven approach to life-science research in space,” said Marshall Smith, CEO of Starlab. “Through Starlab’s platform, we’re helping expand access to sustained microgravity experimentation that supports everything from formulation research to medical technology validation, accelerating the translation of orbital research into terrestrial impact.”
The announcement builds on Starlab’s growing life sciences ecosystem, where microgravity creates conditions that reveal new insights into medicines, materials and biological systems. By enabling controlled experimentation in low Earth orbit, researchers can evaluate performance limits, refine formulations and advance product development pathways that may be difficult to replicate on Earth.
Starlab’s market-driven business model is designed to reduce cost, complexity and risk for researchers and commercial partners. Its single-launch, no-assembly-required architecture enables full certification and operational readiness within weeks from launch, minimizing delays and maximizing efficiency for payload customers. Through its joint venture partners, customers can conduct research aboard the International Space Station today, ensuring a seamless transition to Starlab as its next-generation capabilities come online.
###
About Starlab
Starlab Space is a U.S.-led, global joint venture among Voyager Technologies (NYSE: VOYG), Airbus, Mitsubishi Corporation, MDA Space, Palantir Technologies and Space Applications Services, with strategic partners including Hilton, Journey, Northrop Grumman and The Ohio State University. Starlab is developing a next-generation, AI-enabled commercial space station, aiming to ensure continued human presence in low-Earth orbit and a seamless transition of microgravity science and research alongside the retirement of the International Space Station. Starlab’s advanced, user-driven design and robust capabilities make it a premier platform for scientific discovery and technological advancement in space. For more information, visit starlab-space.com.
About Delta Biosciences
Delta Biosciences is an R&D company operating at the intersection of pharmaceutical innovation and space research. The company develops molecules and advanced biochemical formulations for terrestrial applications while leveraging the space environment to accelerate pharmaceutical research. Delta Biosciences designs and executes life-science missions in space, providing partners with end-to-end capabilities from payload design to post-flight analytics. It builds on prior work with partners such as the European Space Agency and the UK Space Agency, including experiments to be conducted aboard the International Space Station and upcoming commercial LEO platforms. For more information, visit deltabiosciences.com.
MEDIA CONTACT:
Starlab Space
Melissa Price, melissaprice@griffincg.com